Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in ...

A new study published in the European Respiratory Journal showed that there is no connection between combination oral contraceptives (COCs) and asthma in women of reproductive age. However, in ...

The DapaTAVI trial previously showed reduced rates of death or worsening heart failure with dapagliflozin in older adults with aortic stenosis undergoing transcatheter aortic valve implantation (TAVI) ...

The FDA approved Zepzelca and Atezolizumab for ES-SCLC maintenance therapy after successful first-line induction therapy. The Phase III IMforte trial showed a 46% reduction in disease progression risk ...

A new drug combination could significantly delay the progression of a life-threatening form of prostate cancer in men with specific genetic mutations, finds a major international trial led by UCL ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Aprea Therapeutics ( (APRE)) has shared ...

FDA approved Tecentriq and lurbinectedin combination for ES-SCLC maintenance therapy, reducing disease progression and mortality risks significantly. The Phase III IMforte study showed a 46% reduction ...

A new treatment strategy tested by UCLA researchers could offer new hope for men whose prostate cancer has returned after initial treatment. This approach could also help delay the need for hormone ...

Two weeks ago, I attended a symposium in Stockholm organised by a consortium of Singaporean and Swedish universities on the theme of artificial intelligence (AI) and its impact on lifelong learning.

Quantum computing is still in its early stages of development, but researchers have extensively explored its potential uses. A recent study conducted at São Paulo State University (UNESP) in Brazil ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved the combination of lurbinectedin and atezolizumab as first-line maintenance treatment for ...